BUZZ-Olema Pharma climbs on collaboration agreement with Bayer

Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc.

OLMA

0.00

** Shares of Olema Pharmaceuticals OLMA.O rise 1.5% to $13.89 premarket

** The drug developer says it signed a clinical trial and supply agreement with German drugmaker Bayer AG BAYGn.DE for its experimental drug OP-3136

** OP-3136 being developed in combination with Bayer's darolutamide to treat patients with a type of prostate cancer - OLMA

** Under the terms of the agreement, Bayer will supply darolutamide for use in an early to mid-stage study and Olema will lead the conduct of the study

** Up to last close, OLMA down 45.3% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.